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VARYING RATES OF CLOSTRIDIUM DIFFICILE–
ASSOCIATED DIARRHEA AT  
PREVENTION EPICENTER HOSPITALS
SeJean Sohn, MPH; Michael Climo, MD; Daniel Diekema, MD; Victoria Fraser, MD; Loreen Herwaldt, MD; Susan Marino, MS, CIC;  
Gary Noskin, MD; Trish Perl, MD, MSc; Xiaoyan Song, MD, MS; Jerome Tokars, MD, MPH; David Warren, MD, MPH;  
Edward Wong, MD; Deborah S. Yokoe, MD, MPH; Theresa Zembower, MD; Kent A. Sepkowitz, MD, for the Prevention Epicenter Hospitals
BACKGROUND: Clostridium difﬁcile–associated diar-
rhea (CDAD) causes substantial healthcare-associated mor-
bidity. Unlike other common healthcare-associated pathogens, 
little comparative information is available about CDAD rates in 
hospitalized patients. 
OBJECTIVES: To determine CDAD rates per 10,000 patient-
days and per 1,000 hospital admissions at 7 geographically diverse 
tertiary-care centers from 2000 to 2003, and to survey participating 
centers on methods of CDAD surveillance and case deﬁnition.
METHODS: Each center provided speciﬁc information 
for the study period, including case numbers, patient-days, and 
hospital characteristics. Case deﬁnitions and laboratory diagno-
ses of healthcare-associated CDAD were determined by each 
institution. Within institutions, case deﬁnitions remained con-
sistent during the study period. 
RESULTS: Overall, mean annual case rates of CDAD were 
12.1 per 10,000 patient-days (range, 3.1 to 25.1) and 7.4 per 1,000 
hospital admissions (range, 3.1 to 13.1).  No signiﬁcant increases 
were observed in CDAD case rates during the 4-year interval, either 
at individual centers or in the Prevention Epicenter hospitals as a 
whole. Prevention Epicenter hospitals differed in their CDAD case 
deﬁnitions. Different case deﬁnitions used by the hospitals applied 
to a ﬁxed data set resulted in a 30% difference in rates. No associa-
tions were identiﬁed between diagnostic test or case deﬁnition used 
and the relative rate of CDAD at a speciﬁc medical center. 
CONCLUSIONS: Rates of CDAD vary widely at tertiary-
care centers across the United States. No signiﬁcant increases 
in case rates were identiﬁed. The varying clinical and laboratory 
approaches to diagnosis complicated comparisons between hos-
pitals. To facilitate benchmarking and comparisons between in-
stitutions, we recommend development of a more standardized 
case deﬁnition (Infect Control Hosp Epidemiol 2005;26:676-679). 
ABSTRACT
Clostridium difﬁcile–associated diarrhea (CDAD) 
causes substantial healthcare-associated morbidity in many 
hospitals. Patients who acquire CDAD require antibiotic 
therapy, contact isolation, and prolonged hospitalization and 
have a 20% rate of recurrence.1,2 CDAD also imposes a sig-
niﬁcant ﬁnancial burden on healthcare institutions, with an 
estimated cost of $1.1 billion per year in the United States.3 
In addition, according to the Centers for Disease Control 
and Prevention (CDC), the annual rate of healthcare-associ-
ated CDAD has increased in recent years.4-6 
Unlike other common healthcare-associated patho-
gens, such as methicillin-resistant Staphylococcus aureus and 
vancomycin-resistant Enterococcus, there is little compara-
tive information available about CDAD rates in hospitalized 
patients. Such data may be helpful for hospitals seeking to evalu-
ate the effectiveness of their infection control and prevention 
programs and to benchmark their rates against national data.
To address the lack of comparative data, we deter-
mined the range of CDAD rates at Prevention Epicenter hos-
pitals during the 4-year period from January 1, 2000, to De-
cember 31, 2003. In addition, these hospitals were surveyed 
on their methods of CDAD surveillance and case classiﬁca-
tion. The Prevention Epicenter is a consortium of seven aca-
demic medical centers funded by the CDC to address areas 
relevant to infection control and quality promotion.
METHODS 
Each Prevention Epicenter hospital provided speciﬁc 
information for the study period, including case numbers, 
patient-days, and hospital characteristics. All hospitals de-
ﬁned CDAD as a positive laboratory test result for a hospital-
ized, acute care patient with symptoms. Deﬁnition of symp-
toms ranged from physician designation of diarrhea alone 
to the full deﬁnition of the National Nosocomial Infections 
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Surveillance System for nosocomial gastroenteritis with pre-
vious antibiotic exposure. Diagnostic tests differed among 
the various hospitals. Enzyme immunoassay (EIA) testing 
for toxins A and B was used by four centers; each of the re-
maining three centers used cytotoxicity assay, EIA for toxin 
A, or EIA for toxin B. One hospital switched in 2002 from 
cytotoxicity assay to EIA for toxins A and B, whereas another 
switched in 2003 from EIA for toxins A and B to cytotoxicity 
assay.
Prevention Epicenter hospitals were surveyed regard-
ing their criteria for classifying CDAD cases. Relevant variables 
included the length of time between patient admission and 
the collection of incident diagnostic specimens; consideration 
of hospital exposure prior to collection of positive specimens; 
the interval between a previous hospitalization and the point at 
which CDAD was diagnosed; deﬁnition of recurrent cases and 
second incident cases; and categorization of outpatient cases.
The annual percent change was estimated by ﬁtting 
a least squares regression line to the natural logarithm of 
the rate using calendar year as a regressor variable (model: 
y = mx + b, where y = ln [rate] and x = calendar year). The es-
timated annual percent change is equal to 100  (em - 1). The 
null hypothesis of the annual percent change being equal to 
0 (ie, no increase or decrease in the rate) was tested. The 
hypothesis test statistic uses the t distribution of m ÷ SEm, 
where SE is the standard error of m and the number of de-
grees of freedom is equal to the number of calendar years mi-
nus 2.7 Data processing and analyses were performed using 
SPSS software (version 10.0; SPSS, Inc., Chicago, IL).
RESULTS 
The Prevention Epicenter hospitals comprise 5,300 
beds with 1.3 million annual patient-days. Approximately 
1,750 cases of CDAD occur in the Prevention Epicenter 
TABLE 1
ANNUAL CLOSTRIDIUM DIFFICILE INCIDENCE RATES AND PERCENT CHANGE PER 10,000 PATIENT-DAYS AND PER 1,000 
ADMISSIONS




Rate per 10,000 patient-days 25.0 19.5 32.6 23.0 25.1 2.69
Rate per 1,000 admissions 13.7 9.8 16.9 12.0 13.1 1.48
Hospital B
Rate per 10,000 patient-days 5.9 5.8 5.7 5.5 5.7 -2.22*
Rate per 1,000 admissions 3.5 3.4 3.3 2.4 3.1 -10.33
Hospital C
Rate per 10,000 patient-days 4.0 5.9 3.0 4.2 4.3 -5.26
Rate per 1,000 admissions 4.0 5.2 2.6 3.4 3.8 -10.95
Hospital D
Rate per 10,000 patient-days 9.2 9.9 7.1 8.7 8.7 -4.75
Rate per 1,000 admissions 6.7 6.9 4.9 5.9 6.1 -7.12
Hospital E
Rate per 10,000 patient-days 22.0 16.0 20.0 20.9 19.7 0.78
Rate per 1,000 admissions 8.8 6.5 4.6 8.1 7.8 -0.99
Hospital F
Rate per 10,000 patient-days 3.7 1.9 3.5 3.4 3.1 4.40
Rate per 1,000 admissions 5.4 2.7 5.2 5.1 4.6 5.01
Hospital G
Rate per 10,000 patient-days 14.2 12.5 14.6 14.0 13.8 1.09
Rate per 1,000 admissions 9.6 8.7 9.9 9.5 9.4 1.10
Overall
Rate per 10,000 patient-days 12.3 10.8 13.2 12.2 12.1 -0.53
Rate per 1,000 admissions 8.0 6.7 8.0 7.1 7.4 -3.29
*The annual percent change differs from 0 to a statistically signiﬁcant degree (two-sided P < .05).
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hospitals each year, for mean annual rates of 12.1 cases per 
10,000 patient-days (mean range, 3.1 to 25.1) and 7.4 cases 
per 1,000 admissions (mean range, 3.1 to 13.1). During the 
4-year period, no signiﬁcant changes in C. difﬁcile rates 
were seen for the Prevention Epicenter hospitals collec-
tively or by individual medical centers, with one exception. 
Hospital B experienced an annual percent change of -2.22 
in the CDAD rate per 10,000 patient-days that was statisti-
cally signiﬁcant (Table 1). No associations were identiﬁed 
between the diagnostic test or case deﬁnition used and the 
relative rate of CDAD per medical center. 
Prevention Epicenter hospitals differed in their case 
deﬁnitions of healthcare-associated disease. Six centers con-
sidered a case to be healthcare associated if the incident diag-
nostic specimen was collected more than 48 hours after patient 
admission; one center required the specimen to be obtained at 
least 72 hours after admission (Table 2). The Prevention Epi-
center hospitals also were not in agreement about whether 
a recent hospitalization should be given consideration when 
classifying a CDAD case as healthcare associated. Only ﬁve 
of the seven hospitals accounted for prior hospital admissions. 
Furthermore, the interval from a previous discharge to the 
start of symptoms was not uniform across institutions, rang-
ing from 3 to 60 days. The deﬁnition of recurrent cases varied 
widely among the individual Prevention Epicenter hospitals 
and only some of the hospitals included outpatient cases in 
overall healthcare-associated rates (Table 2). 
To examine how extensively case deﬁnition might af-
fect case rates, chart reviews were performed for all incident 
cases of CDAD at one Prevention Epicenter hospital during 
the 2-year period from January 1, 2002, to December 31, 2003 
(n = 370).8 Six different deﬁnitions of healthcare-associated 
CDAD were applied to this cohort and the resultant case 
numbers and rates were determined (Table 3). When the 
strictest deﬁnition of healthcare-associated disease (a posi-
tive test specimen collected 3 or more days after admission) 
was applied, the rate was 8.67 per 10,000 patient-days. When 
more inclusive criteria were used (a positive test result 3 or 
more days after admission or a previous hospitalization within 
30 days of the ﬁrst positive test result), the rate increased to 
10.45 per 10,000 patient-days. With even more inclusive crite-
ria (a positive test result more than 2 days after admission or 
a previous hospitalization within 30 days of the ﬁrst positive 
test result), the rate rose to 11.33 per 10,000 days. Thus, the 
different deﬁnitions of healthcare-associated CDAD used by 
the Prevention Epicenter hospitals applied to a ﬁxed data set 
resulted in a 30% difference in rates. Although these differ-
ences in deﬁnitions did not explain the wide variation of rates 
among the Prevention Epicenter hospitals, the variability in 
deﬁnitions complicates benchmarking. 
DISCUSSION
In contrast to a recent report from the CDC that 
evaluated an earlier time period, we did not ﬁnd signiﬁcant 
increases in CDAD case rates during our 4-year interval 
either at individual centers or in the Prevention Epicenter 
hospitals collectively.5,6 These discrepant ﬁndings may be 
the result of differing methodologies. The CDC reports 
TABLE 2
CLOSTRIDIUM DIFFICILE CASE DEFINITION COMPONENTS 
Hospital A Hospital B Hospital C Hospital D Hospital E Hospital F Hospital G
Diagnostic test Prior to 5/02, 
cytotoxicity as-
say; after 5/02, 
EIA for toxins 
A and B
Cytotoxicity as-
say for toxin B
EIA EIA EIA and 
culture on 
CCFA








> 48 > 48 > 48 > 48 > 48 > 48  72 
Days from previous 
discharge date
 60 for oncol-
ogy patients 
only
 30 and no pre-
vious positive 
assay in 6 mo
 30 NA*  14  3 NA*
“Recurrent” cases 
counted as incidents
Yes Yes Yes Yes Yes Yes No








period and no 





No Yes, if  30 
d since last 
discharge




EIA = enzyme immunoassay; CCFA = cycloserine–cefoxitin–fructose agar; NA = not applicable. 
*Prior hospital admissions not accounted for.
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calculated C. difﬁcile rates using the International Classi-
ﬁcation of Diseases, 9th revision, code diagnoses per dis-
charge, an approach that is inﬂuenced by additional factors 
not reﬂected in rates calculated using only laboratory and 
clinical hospital data. Alternatively, the hospital sample in 
this report may not be large enough to detect a national 
trend.
Direct comparisons among the Prevention Epicenter 
hospitals were hampered by several factors. First, the diag-
nostic tests used by the hospitals varied. No studies to date 
have shown that the use of different diagnostic tests for C. 
difﬁcile has resulted in signiﬁcant differences in CDAD rates. 
However, depending on the clinical and laboratory criteria 
used for the CDAD case deﬁnition, the sensitivities of cell cul-
ture cytotoxin detection and EIA toxin tests range from 67% 
to 100% and 63% to 99%, respectively.9 Clinical and laboratory 
criteria for assessment of C. difﬁcile did vary across the Pre-
vention Epicenter hospitals. We cannot assess whether these 
differences had an appreciable impact on CDAD rates. 
Second, the case deﬁnition for healthcare-associated 
CDAD for each hospital was unique, particularly regarding 
four variables. These include the duration of hospitalization 
prior to incident sample collection, the time from previous 
hospital discharge until the development of symptoms, and 
whether CDAD diagnosed in outpatients was included in sur-
veillance. Moreover, the deﬁnitions of recurrent CDAD and 
second incident cases varied substantially. For institutions 
with relatively high numbers of readmissions, the deﬁnition 
used for differentiation of recurrent CDAD versus incident 
CDAD could have a greater impact on the ﬁnal calculation of 
incident and healthcare-associated rates. Each of these vari-
ables may inﬂuence the rate a given hospital reports and so 
may affect evaluation of an infection control program. 
Other study limitations include the suboptimal sensi-
tivity and speciﬁcity of the various diagnostic CDAD stand-
alone tests and that most of the Prevention Epicenter hospi-
tals are large, mostly urban, tertiary-care teaching facilities 
that may not be representative of hospitals nationally. 
The 7 Prevention Epicenter hospitals documented 
mean annual healthcare-associated CDAD rates of 12.1 
cases per 10,000 patient-days and 7.4 cases per 1,000 ad-
missions, with wide but stable variations between sites. The 
deﬁnitions of healthcare-associated disease used by the 
participating facilities varied considerably. Inherent subtle-
ties are involved in the interpretation and comparison of 
infection rates across institutions (eg, patient case mix and 
potential ascertainment bias of more intensive surveillance 
programs). The variations in operational case classiﬁcation 
outlined here only further hinder the efforts to interpret 
interinstitutional rate differences and preclude the estab-
lishment of a meaningful national benchmark. There is no 
standard case deﬁnition of healthcare-associated CDAD 
in the published guidelines.9-11 We recommend that one 
be developed and that diagnostic tests and testing criteria 
be standardized to allow meaningful comparisons between 
hospitals. We also invite other medical centers to report 
healthcare-associated CDAD rates so that an expected an-
nual rate of CDAD can be better deﬁned. 
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TABLE 3
IMPACT OF DIFFERENT DEFINITIONS OF HEALTHCARE-










A = specimen  72 h after admission 225 8.67
B = A + specimen < 72 h after admis-
sion with hospitalization in previous 14 
d (n = 32)
257 9.91
C = A + specimen < 72 h after admis-
sion with hospitalization in previous 30 
d (n = 46)
271 10.45
D = specimen  48 h after admission 267 10.29
E = D + specimen < 48 h after admis-
sion with hospitalization in previous 14 
d (n = 20)
287 11.06*
F = D + specimen < 48 h after admis-
sion with hospitalization in previous 
30 d (n = 7)
294 11.33†
CDAD = C. difﬁcile–associated diarrhea. 
*Incidence rate ratioA:E = 1.28 (95% conﬁdence interval [CI95], 1.07–1.52). 
†Incidence rate ratioA:F = 1.31 (CI95, 1.10–1.54).
